Solana (NASDAQ:HSDT) Posts Earnings Results, Beats Estimates By $30.75 EPS

Solana (NASDAQ:HSDT) issued its quarterly earnings results on Monday. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of ($26.50) by $30.75, FiscalAI reports. The firm had revenue of $5.23 million during the quarter, compared to analyst estimates of $0.14 million. Solana had a negative return on equity of 699.93% and a negative net margin of 39,358.88%.

Here are the key takeaways from Solana’s conference call:

• Solana Company has staked substantially all of its SOL and reported disciplined outperformance in staking yields—6.8% average net yield in Q4 2025 vs a 6.2% system average, and 7.0% YTD 2026 vs 6.0%—generating steady on‑chain revenue.
• Active capital markets and treasury management grew SOL per share by about 14% from the strategy start (Sept 18, 2025) to March 27, 2026, with roughly 2.33 million SOL on hand (Mar 27) and $7M of cash/stablecoins.
• GAAP results show large volatility and non‑cash charges—Q4 operating loss of $201.1M (including $178.3M unrealized digital asset losses)—and Q4 net income of $325.6M was driven by a $526.3M fair‑value gain on PIPE stapled warrants, while FY2025 ended with a $40.9M net loss.
• The company announced strategic growth initiatives—the Anchorage Digital + Kamino tri‑party custody/borrowing arrangement (aimed to unlock an incremental 100–200 bps of yield) and the regional Pacific Backbone low‑latency node build to target Asia‑Pacific institutional services within 12–18 months.

Solana Stock Down 3.1%

Shares of Solana stock opened at $1.86 on Tuesday. Solana has a twelve month low of $1.74 and a twelve month high of $366.68. The company’s 50 day moving average is $2.26 and its 200 day moving average is $5.68. The company has a market cap of $76.82 million, a price-to-earnings ratio of 0.00 and a beta of 1.08.

Hedge Funds Weigh In On Solana

Several institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD bought a new stake in Solana during the fourth quarter valued at approximately $46,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Solana in the 4th quarter worth $88,000. Aristides Capital LLC bought a new position in Solana in the 4th quarter worth $137,000. XTX Topco Ltd purchased a new position in Solana during the fourth quarter valued at $140,000. Finally, Marshall Wace LLP bought a new stake in Solana during the fourth quarter valued at about $195,000. Institutional investors own 18.63% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Solana in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Solana

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.